Clinical Trial

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-06-20; most recent amendment 2026-03-24.
Trial Details
NCT Number NCT07043946
Lead Sponsor Climb Bio, Inc.
Conditions Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19
Enrollment 24 participants
Start Date 2025-06-30
Primary Completion 2027-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-27